Synthesis, Radiolabeling, and In Vivo Pharmacokinetic Evaluation of the Amyloid Beta Radioligand [11C]AZD4694 in Nonhuman Primates

Molecular Imaging and Biology - Tập 16 - Trang 173-179 - 2013
Magnus Schou1, Katarina Varnäs2, Johan Sandell3, Peter Johnström1, Zsolt Cselenyi1, Samuel Svensson4, Ryuji Nakao2, Nahid Amini2, Linda Bergman2, Anna Sumic2, Balazs Gulyas2, Eva Lindström-Böö1, Christer Halldin2, Lars Farde1
1AstraZeneca Translational Science Centre, PET Centre of Excellence, Department of Clinical Neuroscience, Karolinska University Hospital, Karolinska Institutet, Stockholm, Sweden
2Psychiatry Section, Department of Clinical Neuroscience, Karolinska Institutet, Stockholm, Sweden
3Isotope Chemistry, Screening and Profiling, Global DMPK, AstraZeneca, Research & Development, Innovative Medicines, Södertälje, Sweden
4CNSP iMed, AstraZeneca, Research & Development, Innovative Medicines, Södertälje, Sweden

Tóm tắt

[18F]AZD4694 (2-(2-18F-fluoro-6-(methylamino)-3-pyridyl)benzofuran-5-ol) is a radioligand suitable for imaging of amyloid beta deposits in the living human brain using positron emission tomography (PET). Here, we report the preparation and pharmacokinetic profile of its carbon-11 (t 1/2  = 20.4 min) labeled isotopolog [11C]AZD4694 and compare [11C]AZD4694 with the hitherto most widely applied amyloid PET radioligand [11C]Pittsburgh Compound B (PiB). The immediate unlabeled precursor to [11C]AZD4694 was prepared in a four-step convergent synthesis. Subsequent N-11C-methylation of this precursor with [11C]methyl iodide yielded [11C]AZD4694, which after isolation and formulation was injected into cynomolgus monkeys. The radioactivity in nonhuman primate brain following injection of [11C]AZD4694 and [11C]PiB was measured using PET. [11C]AZD4694 was prepared in a 60 % incorporation yield. In a head to head comparison with [11C]PiB, it appeared that [11C]AZD4694 displayed slightly lower nonspecific binding in white matter than [11C]PiB as well as more rapid pharmacokinetics in the brain. The advantageous pharmacokinetic profile and low nonspecific binding render [11C]AZD4694 a promising PET radioligand for imaging of amyloid beta in the human brain with PET.

Tài liệu tham khảo

Friedland RP, Kalaria R, Berridge M et al (1997) Neuroimaging of vessel amyloid in Alzheimer's disease. Ann N Y Acad Sci 826:242–247 Klunk WE, Engler H, Nordberg A et al (2004) Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound-B. Ann Neurol 55:306–319 Shoghi-Jadid K, Small GW, Agdeppa ED et al (2002) Localization of neurofibrillary tangles and beta-amyloid plaques in the brains of living patients with Alzheimer's disease. Am J Geriatr Psychiatry 10:24–35 Swahn BM, Wensbo D, Sandell J et al (2010) Synthesis and evaluation of 2-pyridylbenzothiazole, 2-pyridylbenzoxazole and 2-pyridylbenzofuran derivatives as (11)C-PET imaging agents for beta-amyloid plaques. Bioorg Med Chem Lett 20:1976–1980 Nyberg S, Jonhagen ME, Cselenyi Z et al (2009) Detection of amyloid in Alzheimer's disease with positron emission tomography using [11C]AZD2184. Eur J Nucl Med Mol Imaging 36:1859–1863 Jureus A, Swahn BM, Sandell J et al (2010) Characterization of AZD4694, a novel fluorinated Abeta plaque neuroimaging PET radioligand. J Neurochem 114:784–794 Swahn BM, Sandell J, Pyring D et al (2012) Synthesis and evaluation of pyridylbenzofuran, pyridylbenzothiazole and pyridylbenzoxazole derivatives as F-18-PET imaging agents for beta-amyloid plaques. Bioorg Med Chem Lett 22:4332–4337 Nelissen N, Van Laere K, Thurfjell L et al (2009) Phase 1 study of the Pittsburgh compound B derivative 18F-flutemetamol in healthy volunteers and patients with probable Alzheimer's disease. J Nucl Med 50:1251–1259 Rowe CC, Ackerman U, Browne W et al (2008) Imaging of amyloid beta in Alzheimer's disease with 18F-BAY94-9172, a novel PET tracer: proof of mechanism. Lancet Neurol 7:129–135 Choi SR, Golding G, Zhuang Z et al (2009) Preclinical properties of 18F-AV-45: a PET agent for Abeta plaques in the brain. J Nucl Med 50:1887–1894 Cselenyi Z, Jonhagen ME, Forsberg A et al (2012) Clinical validation of 18F-AZD4694, an amyloid-beta-specific PET radioligand. J Nucl Med 53:415–424 Andersson J, Truong P, Halldin C (2009) In-target produced [(11)C]methane: increased specific radioactivity. Appl Radiat Isot 67:106–110 Sandell J, Langer O, Larsen P et al (2000) Improved specific radioactivity of the PET radioligand [C-11]FLB 457 by use of the GE Medical Systems PETtrace MeI MicroLab. J Label Compd Radiopharm 43:331–338 Mathis CA, Wang Y, Holt DP, Huang GF, Debnath ML, Klunk WE (2003) Synthesis and evaluation of 11C-labeled 6-substituted 2-arylbenzothiazoles as amyloid imaging agents. J Med Chem 46:2740–2754 Andersson JD, Varnas K, Cselenyi Z et al (2010) Radiosynthesis of the candidate beta-amyloid radioligand [(11)C]AZD2184: Positron emission tomography examination and metabolite analysis in cynomolgus monkeys. Synapse 64:733–741 Clark JD (1996) Guide for the care and use of laboratory animals. National Academy Press, Washington Innis RB, Cunningham VJ, Delforge J et al (2007) Consensus nomenclature for in vivo imaging of reversibly binding radioligands. J Cereb Blood Flow Metab 27:1533–1539 Andree B, Halldin C, Pike VW, Gunn RN, Olsson H, Farde L (2002) The PET radioligand [carbonyl-(11)C]desmethyl-WAY-100635 binds to 5-HT(1A) receptors and provides a higher radioactive signal than [carbonyl-(11)C]WAY-100635 in the human brain. J Nucl Med 43:292–303 Osman S, Lundkvist C, Pike VW et al (1996) Characterization of the radioactive metabolites of the 5-HT1A receptor radioligand, [O-methyl-11C]WAY-100635, in monkey and human plasma by HPLC: comparison of the behaviour of an identified radioactive metabolite with parent radioligand in monkey using PET. Nucl Med Biol 23:627–634 Cselenyi Z, Jonhagen ME, Forsberg A et al (2010) Quantification and wavelet-aided parametric imaging of cerebral amyloid using the HRRT PET-system and [18F]AZD4694. NeuroImage 52:S142–S142 Johnson AE, Jeppsson F, Sandell J et al (2009) AZD2184: a radioligand for sensitive detection of beta-amyloid deposits. J Neurochem 108:1177–1186 Cheng Y, Ono M, Kimura H, Kagawa S, Nishii R, Saji H (2010) A novel 18F-labeled pyridyl benzofuran derivative for imaging of beta-amyloid plaques in Alzheimer's brains. Bioorg Med Chem Lett 20:6141–6144 Ono M, Kung MP, Hou C, Kung HF (2002) Benzofuran derivatives as Abeta-aggregate-specific imaging agents for Alzheimer's disease. Nucl Med Biol 29:633–642 Zoghbi SS, Shetty HU, Ichise M et al (2006) PET imaging of the dopamine transporter with F-18-FECNT: A polar radiometabolite confounds brain radioligand measurements. J Nucl Med 47:520–527 Osman S, Lundkvist C, Pike VW et al (1998) Characterisation of the appearance of radioactive metabolites in monkey and human plasma from the 5–HT1A receptor radioligand, [carbonyl-11C]WAY-100635–explanation of high signal contrast in PET and an aid to biomathematical modelling. Nucl Med Biol 25:215–223